Nature Biotechnology is a peer-reviewed scientific journal published by Nature Portfolio.《自然-生物技术》（Nature Biotechnology）是一本由自然科研（Nature Portfolio）出版的同行评审科学期刊。
Published monthly, it is one of the leading international academic journals in the field of biotechnology and applied life sciences.该期刊为月刊，是生物技术与应用生命科学领域的顶尖国际学术期刊之一。
Nature Biotechnology covers breakthroughs across the full spectrum of science, engineering, and business in biotechnology.《自然-生物技术》发表涵盖生物技术科学、工程和商业全领域的突破性研究成果。
Key subject areas include genomics and genome editing, synthetic biology, protein engineering, and stem cell research.该刊关注的学科重点包括基因组学与基因组编辑、合成生物学、蛋白质工程以及干细胞研究。
It also features critical advances in biopharmaceuticals, drug delivery, bioinformatics, high-throughput screening, and agricultural biotechnology.它还刊载生物制药、药物递送、生物信息学、高通量筛选与农业生物技术等方向的关键进展。
In addition to original research papers, the journal publishes reviews, policy analyses, patent overviews, and market commentaries focusing on commercialization and investment.除原始研究论文外，期刊还刊发评论、政策分析、专利综述以及关注生物技术产业化与投资的市场分析文章。
The journal was originally launched by Nature Publishing Group in 1983 under the title Bio/Technology.该期刊最初由自然出版集团于1983年创刊，原名为《Bio/Technology》。
As applied research in molecular biology and recombinant DNA rapidly expanded, the journal was formally renamed Nature Biotechnology in 1996.随着分子生物学与重组DNA技术应用研究的迅速扩展，期刊于1996年正式更名为《自然-生物技术》（Nature Biotechnology）。
The renaming marked an evolution toward higher academic standards and deeper integration with fundamental research.更名标志着其向更高学术标准和更深基础科研交叉融合的方向升级。
Over subsequent decades, the journal documented milestone leaps including CRISPR gene editing, mRNA therapeutics, and single-cell multiomics.在此后的数十年中，该期刊见证并报道了CRISPR基因编辑、mRNA疗法及单细胞多组学等诸多里程碑式的科技飞跃。
Nature Biotechnology is managed by a team of full-time professional scientific editors based in offices including New York and London.《自然-生物技术》拥有一支常驻于纽约和伦敦等办事处的全职专业科学编辑团队。
Senior scientific editor Andrew Marshall has long served as Chief Editor, guiding the overall academic and strategic direction of the publication.资深科学编辑安德鲁·马歇尔（Andrew Marshall）长期担任该期刊的总编辑，负责把控期刊的整体学术与战略方向。
The in-house editorial staff works closely with external peer reviewers to evaluate manuscripts for scientific novelty, methodological rigor, and transformative impact.全职内部编辑与外部同行评审专家紧密合作，共同评估论文的原创性、严谨性以及对生物技术领域的潜在影响力。